COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,763 Articles (22,502 medRxiv, 8,261 bioRxiv)

Most recent first Previous |  Page 968: Articles 9671-9680  | Next

Daily Lactobacillus Probiotic versus Placebo in COVID-19-Exposed Household Contacts (PROTECT-EHC): A Randomized Clinical Trial
Wischmeyer, P. E., Tang, H., Ren, Y., Bohannon, L., Ramirez, Z. E., Andermann, T. M., Messina, J. A., Sung, J. A., Jensen, D., Jung, S.-H., Artica, A., Britt, A., Bush, A., Johnson, E., Lew, M. V., Miller, H. M., Pamanes, C. E., Racioppi, A., Zhao, A. T., Surana, N. K., Sung, A. D.
10.1101/2022.01.04.21268275 — Posted: 2022-01-05
Safety and immunogenicity of anti-SARS CoV-2 conjugate vaccine SOBERANA 02 in a two-dose or three-dose heterologous scheme in adults: Phase IIb Clinical Trial
Eugenia-Toledo-Romani, M., Garcia-Carmenate, M., Verdecia-Sanchez, L., Perez-Rodriguez, S., Rodriguez-Gonzalez, M., Valenzuela-Silva, C., Paredes-Moreno, B., Sanchez-Ramirez, B., Gonzalez-Mugica, R., Hernandez-Garcia, T., Orosa-Vazquez, I., Diaz-Hernandez, M., Perez-Guevara, M. T., Enriquez-Puertas, J., Noa-Romero, E., Palenzuela-Diaz, A., Baro-Roman, G., Mendoza-Hernandez, I., Munoz, Y., Gomez-Maceo, Y., Santos Vega, B. L., Fernandez-Castillo, S., Climent-Ruiz, Y., Rodriguez-Noda, L. M., Santana-Mederos, D., Garcia-Vega, Y., Wu-Chen, G., Doroud, D., Biglari, A., Boggiano-Ayo, T., Valdes-Balbin, Y., Garcia-Rivera, D., Verez-Bencomo, V.
10.1101/2022.01.01.21268271 — Posted: 2022-01-05
Discordant SARS-CoV-2 PCR and Rapid Antigen Test Results When Infectious: A December 2021 Occupational Case Series
Adamson, B. J., Sikka, R., Wyllie, A. L., Premsrirut, P. K.
10.1101/2022.01.04.22268770 — Posted: 2022-01-05 Discussion: Onsite
Comparison of infectious SARS-CoV-2 from the nasopharynx of vaccinated and unvaccinated individuals
Pena-Hernandez, M. A., Klein, J., Malik, A., Coppi, A., Kalinich, C. C., Vogels, C. B. F., Silva, J., Yale SARS-CoV-2 Genomic Surveillance Initiative, , Peaper, D. R., Landry, M., Wilen, C., Grubaugh, N. D., Schulz, W. L., Omer, S. B., Iwasaki, A.
10.1101/2021.12.28.21268460 — Posted: 2022-01-04 Discussion: Onsite
The runaway evolution of SARS-CoV-2 leading to the highly evolved Delta strain
Ruan, Y., Hou, M., Tang, X., He, X., Lu, X., Lu, J., Wu, C.-I., Wen, H.
10.1101/2021.12.30.474592 — Posted: 2022-01-04
Structural basis of Omicron neutralization by affinity-matured public antibodies
Sheward, D. J., Pushparaj, P., Das, H., Kim, C., Kim, S., Hanke, L., Dyrdak, R., McInerney, G. M., Albert, J., Murrell, B., Karlsson Hedestam, G. B., Hällberg, B. M.
10.1101/2022.01.03.474825 — Posted: 2022-01-04
Structural and computational insights into the SARS-CoV-2 Omicron RBD-ACE2 interaction
wang, x., Wang, T., Ge, J., Zhang, L., Lan, J., He, X., Ren, Y., Wang, Z., Zhou, H., Fan, S., Zhu, C., Liu, D., Shao, B., Liu, T.-Y., Wang, Q.
10.1101/2022.01.03.474855 — Posted: 2022-01-04
Host kinase CSNK2 is a target for inhibition of pathogenic β-coronaviruses including SARS-CoV-2
Yang, X., Dickmander, R. J., Bayati, A., Taft-Benz, S. A., Smith, J. L., Brown, J. W., Lenarcic, E. M., Yount, B. L., Chang, E., Axtman, A. D., Baric, R. S., Heise, M. T., McPherson, P. S., Moorman, N. J., Willson, T. M.
10.1101/2022.01.03.474779 — Posted: 2022-01-04
A synthetic bispecific antibody capable of neutralizing SARS-CoV-2 Delta and Omicron
Yuan, T. Z., Lucas, C., Monteiro, V. S., Iwasaki, A., Yang, M. L., Nepita, H. F., Lujan Hernandez, A. G., Taft, J. M., Frei, L., Reddy, S. T., Weber, C., Malobisky, K. P., Mesquita, R., Sato, A.
10.1101/2022.01.04.474803 — Posted: 2022-01-04
Maternal cytokine response after SARS-CoV-2 infection during pregnancy
Gigase, F. A. J., Molenaar, N. M., Missall, R. D., Rommel, A.-S., Lieb, W., Ibroci, E., Ohrn, S., Lynch, J., Krammer, F., Brody, R., Jessel, R. H., Sperling, R. S., Lesseur, C., Callipari, F., Galang, R. R., Snead, M. C., Janevic, T., Stone, J., Howell, E. A., Chen, J., Pop, V. J. M., Dolan, S. M., Bergink, V., De Witte, L. D.
10.1101/2022.01.04.474908 — Posted: 2022-01-04

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).